All | Cluster 1 | Cluster 2 | Cluster 3 | Cluster 4 | Cluster 5 | Cluster 6 | Cluster 7 | p-value | |
Subjects n | 20 164 | 3386 | 3488 | 5053 | 1600 | 2017 | 2553 | 2067 | |
Cardiovascular comorbidities % | |||||||||
Systemic hypertension | 47.2 | 80.2 | 86.3 | 6.3 | 73.6 | 81.5 | 7.4 | 14.1 | <0.001 |
Ischaemic heart disease | 9.1 | 14.5 | 12.2 | 0.7 | 11.2 | 28.3 | 1.9 | 1.9 | <0.001 |
Status post myocardial infarction | 2.4 | 3.3 | 3.4 | 0.1 | 1.7 | 9.9 | 0.2 | 0.2 | <0.001 |
Cardiac failure | 2.7 | 4.5 | 3.9 | 0.1 | 4.1 | 8.5 | 0.2 | 0.2 | <0.001 |
TIA or stroke | 2.3 | 2.9 | 4.2 | 0.1 | 3.1 | 6.3 | 0.7 | 0.7 | <0.001 |
Valvular heart disease | 1.4 | 1.9 | 1.9 | 0.1 | 1.9 | 4.4 | 0.6 | 0.4 | <0.001 |
Left ventricular hypertrophy | 1.4 | 1.8 | 1.7 | 0.6 | 1.1 | 2.6 | 0.7 | 2.0 | <0.001 |
Pulmonary hypertension | 0.5 | 0.7 | 0.8 | 0 | 0.6 | 1.5 | 0 | 0.3 | <0.001 |
Metabolic comorbidities % | |||||||||
Hyperlipidaemia | 23.2 | 62.5 | 0.1 | 6.7 | 45.0 | 46.2 | 13 | 7.4 | <0.001 |
Diabetes, noninsulin dependent | 13.4 | 27.1 | 0 | 3.5 | 39.1 | 39.2 | 3.1 | 3.6 | <0.001 |
Diabetes, insulin dependent | 2.4 | 4.8 | 0 | 0.4 | 5.8 | 9.0 | 0.4 | 0.6 | <0.001 |
Hyperuricaemia | 3.3 | 9.4 | 0 | 0.7 | 5.0 | 9.0 | 1.1 | 0.3 | <0.001 |
Pulmonary comorbidities % | |||||||||
Asthma | 5.7 | 4.8 | 5.8 | 3.4 | 12.4 | 5.4 | 5.4 | 7.5 | <0.001 |
COPD | 5.7 | 8.6 | 6.5 | 2.9 | 6.4 | 10.5 | 3.2 | 3.8 | <0.001 |
Respiratory failure | 0.8 | 0.9 | 0.8 | 0.2 | 1.4 | 1.4 | 0.8 | 0.6 | <0.001 |
Other comorbidities % | |||||||||
Malignant disease | 2.0 | 0.7 | 1.5 | 0 | 4.7 | 5.7 | 4.0 | 1.9 | <0.001 |
Inflammatory disease | 1.9 | 0.8 | 1.0 | 0 | 6.0 | 3.5 | 4.0 | 2.0 | <0.001 |
Neurological disease | 4.8 | 2.2 | 3.2 | 0 | 10.1 | 9.1 | 14.7 | 2.2 | <0.001 |
Gastrointestinal disease | 8.6 | 2.1 | 2.8 | 0 | 24 | 25.5 | 21.4 | 4.6 | <0.001 |
Psychiatric disease | 9.5 | 3.2 | 6.0 | 0 | 26.1 | 9.5 | 33.3 | 5.3 | <0.001 |
TIA: transitory ischaemic attack.